NNC0365-3769 (Mim8)
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Haemophilia A
Conditions
Haemophilia A, Haemophilia A With Inhibitors
Trial Timeline
Dec 2, 2021 → Dec 17, 2024
NCT ID
NCT05053139About NNC0365-3769 (Mim8)
NNC0365-3769 (Mim8) is a phase 3 stage product being developed by Novo Nordisk for Haemophilia A. The current trial status is completed. This product is registered under clinical trial identifier NCT05053139. Target conditions include Haemophilia A, Haemophilia A With Inhibitors.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05681845 | Phase 1 | Completed |
| NCT05053139 | Phase 3 | Completed |
Competing Products
20 competing products in Haemophilia A
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Mim8 | Novo Nordisk | Phase 3 | 76 |
| Turoctocog alfa | Novo Nordisk | Phase 3 | 76 |
| Turoctocog alfa pegol | Novo Nordisk | Pre-clinical | 22 |
| Mim8 B, 10 mg/mL + Mim8 B, 100 mg/mL + Mim8 B, placebo | Novo Nordisk | Phase 1 | 32 |
| Turoctocog alfa pegol | Novo Nordisk | Pre-clinical | 22 |
| Concizumab | Novo Nordisk | Phase 3 | 76 |
| Concizumab | Novo Nordisk | Phase 3 | 76 |
| turoctocog alfa pegol (N8-GP) | Novo Nordisk | Phase 3 | 76 |
| Concizumab | Novo Nordisk | Phase 3 | 76 |
| Esperoct | Novo Nordisk | Pre-clinical | 22 |
| NNC0442-0344 A | Novo Nordisk | Phase 1 | 32 |
| NNC0365-3769 (Mim8) PPX | Novo Nordisk | Phase 3 | 76 |
| Concizumab | Novo Nordisk | Pre-clinical | 22 |
| Refixia® | Novo Nordisk | Pre-clinical | 22 |
| NNC0442-0344 A + Placebo | Novo Nordisk | Phase 1 | 32 |
| Mim8 | Novo Nordisk | Phase 3 | 76 |
| Turoctocog alfa pegol (N8-GP) | Novo Nordisk | Pre-clinical | 22 |
| Nonacog beta pegol | Novo Nordisk | Pre-clinical | 22 |
| Concizumab | Novo Nordisk | Pre-clinical | 22 |
| Turoctocog alfa | Novo Nordisk | Pre-clinical | 22 |